Editas Medicine and Azzur Group Announce a Multi-year Agreement for EDIT-301 and EDIT-201 Manufacturing

CAMBRIDGE, Mass., and WALTHAM, Mass., July 07, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, and Azzur Cleanrooms on Demand (COD), an Azzur Group company, today announced the companies have entered a multi-year agreement for current Good Manufacturing Practice (cGMP)-compliant cleanroom space for Editas Medicine in Azzur’s Waltham site. Editas Medicine will utilize the space and Azzur’s services to execute pre-clinical and early-phase clinical manufacturing activities for its cell medicines, including EDIT-301 in development for the treatment of sickle cell disease and beta thalassemia and EDIT-201, a healthy donor natural killer (HDNK) cell medicine, in development for solid tumor cancers.

“Manufacturing and quality management are both essential components of making medicines. As we advance several innovative cell medicines towards the clinic and to the patients who are living with diseases of unmet medical need, Azzur Cleanrooms on Demand gives us dedicated manufacturing space for our pre-clinical and early-phase clinical manufacturing activities while providing us with flexibility and control, all in a cGMP-compliant space,” said Harry Gill, Senior Vice President, Operations, Editas Medicine.  

“Azzur Cleanrooms on Demand supports production for early-phase partners, helping accelerate their time to clinic and eventually to market, while providing cGMP services, including facility management, asset management, consulting, and materials management services, as needed. We are excited our solution can help Editas as they advance several innovative medicines to the clinic,” said Ravi Samavedam, President, Azzur Cleanrooms on Demand.

About Editas Medicine
As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cpf1 (also known as Cas12a) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.